Skin Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Skin Neoplasms. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Skin Neoplasms receives a directional score of 57/100, combining unmet need (58/100), competitive intensity (96/100) and market attractiveness (95/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Tumors or cancer of the SKIN.

The reproducible record is Patsnap disease ID c50c74488b3b427b9a7b4260d76fa188 and MeSH identifier D012878. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Recent global patterns in skin cancer incidence, mortality, and prevalence

tions to 2040. JAMA Dermatol 2022;158:495–503. doi: 10.1001/ jamadermatol.2022.0160. 14. Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of cuta- neous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol 2014;28:1170–1178. doi: 10.1111/jdv.12236. 15. de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemi- ology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003;107:119–126. doi: 10.1002/ijc.11360. 16. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (Keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015;151:1081– 1086. doi: 10.1001/jamadermatol.2015.1187. 17. Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin 2012;30:355–361. doi: 10.1016/j. det.2012.04.001. 18. Cakir BÖ, Adamson P, Cingi C. Epidemiology and economic bur- den of nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2012;20:419–422. doi: 10.1016/j.fsc.2012.07.004. 19. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr., Gold- man ND, Acostamadiedo JM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425–429. doi: 10.1067/mjd.2003.186. 20. Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol 2020;156:57–64. doi: 10.1001/jamaderma

Review source

Epidemiology evidence 2: Burden of Skin Disease — China, 1990−2019

To date, there has been no national-level epidemiological survey of skin diseases and their burden in China. Using data from the 2019 Global Burden of Disease (GBD 2019) and China’s 2010 national census as the standard population, this study estimated age-standardized incidence, prevalence, mortality, and burden of skin disease in 1990 and 2019. In 2019, there were an estimated 5,393 deaths, 369,127,390 cases of skin diseases, 8,264,702 person- years of disability adjusted life years (DALYs) lost, 8,167,678 person-years of years living with disability (YLDs), and 97,024 person-years of years of life lost (YLLs) caused by skin diseases. In 2019, the age group of 15–49 years had the most number of cases of skin disease, DALYs and YLDs, whereas people over 70 years had the highest incidence, prevalence, and mortality for skin disease. DALYs steadily increased between 1990 and 2019, while DALYs rate declined. The ranking of DALYs by skin disease varied by age group, indicating that the specific disease burdens varied by age. The GBD provided estimates of incidence, prevalence, mortality, YLLs, YLDs, and DALYs lost due to 369 diseases or injuries in 204 countries and territories (1). GBD divided skin and subcutaneous tissue diseases into 12 categories: 1) dermatitis; 2) psoriasis; 3) scabies; 4) fungal skin diseases; 5) viral skin diseases; 6) acne vulgaris; 7) alopecia areata; 8) pruritus; 9) urticaria; 10) decubitus ulcers; 11) bacterial skin diseases; and 12) other skin and subcutaneous diseases (1–2). In China, skin disease data were obtained from epidemiological surveillanc

Review source

Epidemiology evidence 3: Demographics, Trends, and Cardiovascular Mortality in Kaposi Sarcoma Patients in the United States: An Analysis of Surveillance, Epidemiology, and End Results Database Demographics, Trends, and Cardiovascular Mortality inKaposi Sarcoma Patients in the United States: AnAnalysis of Surveillance, Epidemiology, and End ResultsDatabase

1. O. Radu and L. Pantanowitz, “Kaposi Sarcoma,” Archives of Pathology & Laboratory Medicine 137, no. 2 (February 2013): 289–294, https://doi. org/10.5858/arpa.2012-0101-RS. 2. E. Cesarman, B. Damania, S. E. Krown, J. Martin, M. Bower, and D. Whitby, “Kaposi Sarcoma,” Nature Reviews Disease Primers 5, no. 1 (January 2019): 9, https://doi-org.libproxy1.nus.edu.sg/10.1038/s41572-019-0060-9. 3. R. Vangipuram and S. K. Tyring, “Epidemiology of Kaposi Sarcoma: Review and Description of the Nonepidemic Variant,” International Journal of Dermatology 58, no. 5 (May 2019): 538–542, https://doi-org.libproxy1.nus.edu.sg/ 10.1111/ijd.14080. 4. E. A. Mesri, E. Cesarman, and C. Boshoff, “Kaposi's Sarcoma and Its Associated Herpesvirus,” Nature Reviews Cancer 10, no. 10 (October 2010): 707–719, https://doi-org.libproxy1.nus.edu.sg/10.1038/nrc2888. 5. S. Peprah, E. A. Engels, M. J. Horner, et al., “Kaposi Sarcoma Incidence, Burden, and Prevalence in United States People With HIV, 2000‐2015,” Cancer Epidemiology, Biomarkers & Prevention 30, no. 9 (September 2021): 1627–1633, https://doi-org.libproxy1.nus.edu.sg/10.1158/1055-9965.EPI-21-0008. 6. N. Iftode, M. A. Rădulescu, Ș. S. Aramă, and V. Aramă, “Update on Kaposi Sarcoma‐Associated Herpesvirus (KSHV or HHV8) ‐ Review,” Romanian Journal of Internal Medicine 58, no. 4 (December 2020): 199– 208, https://doi-org.libproxy1.nus.edu.sg/10.2478/rjim-2020-0017. 7. D. L. White, A. Oluyomi, K. Royse, et al., “Incidence of AIDS‐Related Kaposi Sarcoma in All 50 United States From 2000 to 2014,” JAIDS Journal of Acquired Immune Deficiency Syndromes 81, no. 4 (August 2019): 387–394, https://doi-org.libproxy1.nus.edu.sg/10.1097/QAI.0000000000002050. 8. A. W. Armstrong, K. H. L

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Skin Neoplasms, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Skin Neoplasms thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: COL1A1

Type I collagen is a member of group I collagen (fibrillar forming collagen).

The mechanism anchor is COL1A1, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 5405 registered studies.

• NCT07761871 — Exercise and Nutritional Intervention in Patients With Melanoma Receiving Immunotherapy (MEL-FIT-IO); Recruiting; Not Applicable; sponsor Institute of Oncology Ljubljana; enrollment 40.
• NCT07760012 — 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors (SORB-PET); Recruiting; Not Applicable; sponsor Peking University Third Hospital; enrollment 50.
• NCT07757386 — MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and Management (MelaMEd); Completed; Not Applicable; sponsor Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori, Intergruppo Melanoma Italiano; enrollment 1531.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

The query returned 6 directly matched 2023–2026 transactions.

• PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma (2024-09-17). Review stage, rights, territory, milestones and economics before using it as a comparable.
• Pathos Expands Pipeline With Worldwide License of Phase 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor (2024-08-15). Review stage, rights, territory, milestones and economics before using it as a comparable.
• CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) (2024-05-07). Review stage, rights, territory, milestones and economics before using it as a comparable.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate COL1A1 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Skin Neoplasms merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Skin Neoplasms is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.